This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Bristol-Myers Bolsters Biologics in Medarex Buy

Bristol-Myers Squibb (BMY) is buying biotech firm Medarex (MEDX) for $2.1 billion to bolster the U.S. drugmaker's drug pipeline and capability to produce biologic drugs.

The deal, announced Wednesday night, values Medarex at $16 a share, a 90% premium to the company's $8.40 a share closing price. A $2.4 billion purchase price, which Bristol-Myers will pay in cash, is offset by $300 million on Medarex's books.

Medarex specializes in the production of protein-based drugs made in living cells engineered to produce human antibodies. These so-called biologic drugs are different from the chemical-based drugs typically developed and marketed by large pharmaceutical companies.

Bristol-Myers and Medarex already were partners on one such drug, ipilimumab, currently in a phase III study of skin cancer patients.

"Medarex's technology platform, people and pipeline provide a strong complement to our company's biologics strategy, specifically in immuno-oncology," said Bristol-Myers CEO James Cornelius, in a statement.

Medarex hasn't successfully developed any drugs on its own yet, but three drugs it helped manufacture for partners have been approved recently -- Johnson & Johnson's (JNJ) Simponi and Stelara and Novartis' (NVS) Ilaris. Medarex receives royalties on the sale of these products.

The company has seven drugs of its own in current clinical trials and another three under development by partners.

Bristol-Myers' decision to acquire Medarex, a biotech drug development partner, comes a little less than a year after Bristol-Myers was outbid to acquire another partner, the biotech firm ImClone Systems.

Eli Lilly (LLY) purchased ImClone, developer of the cancer drug Erbitux, for $6.5 billion -- a bid that trumped Bristol-Myer's $4.7 billion bid.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs